Suggestions
Alain Bendavid, PhD
Life Sciences Intellectual Property Professional | Originator of Costimulatory/Advanced-Generation CAR T Cell Therapy
Alain Bendavid, PhD is a prominent figure in the life sciences intellectual property field, currently serving as the Director of Intellectual Property at Medicenna Therapeutics Corp.1 He is widely recognized for his significant contributions to the development of CAR T cell therapy, particularly in the area of costimulatory and advanced-generation approaches.23
Professional Background
Dr. Bendavid's expertise lies in several key areas:
Intellectual Property Strategy:: He is highly experienced in developing and managing US and international patent portfolios, with a focus on substantive prosecution and analytics across major jurisdictions.1
CAR T Cell Therapy:: Alain Bendavid is credited as the originator of costimulatory and advanced-generation CAR T cell therapy.23 This groundbreaking work has positioned him as a pioneer in the field of cancer immunotherapy.
Solid Tumor Treatment:: His research interests extend to innovative approaches for treating solid tumors, including the use of functionalized nitinol thin films in combination with CAR-T cells.4
Research and Innovation
Dr. Bendavid's work encompasses cutting-edge developments in cancer treatment:
- He has been involved in research on personalized cell therapy combinations for chronic lymphocytic leukemia (CLL) patients, achieving complete remission in some cases.5
- His innovative approach includes exploring the use of nitinol thin films functionalized with CAR-T cells for solid tumor treatment, demonstrating his commitment to advancing cancer therapies.4
Professional Network
Alain Bendavid maintains an active presence in the scientific community:
- He is based in the Toronto, Canada area.6
- His LinkedIn profile (username: abendavidphd) serves as a platform for sharing insights and connecting with other professionals in the field.12
- He also engages with the scientific community on Twitter under the handle @ABendavidPhD.3
Dr. Bendavid's work at the intersection of intellectual property and advanced cancer therapies positions him as a key figure in the ongoing development of innovative treatments for challenging cancers.
Highlights
Congratulations to the team.
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. N Engl J Med 2023; 388:1284-1295. https://lnkd.in/ger76Hdv
CAR-NK clinical trial:
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu, David Marin, Pinaki Banerjee, Homer A. Macapinlac, Philip Thompson, Rafet Basar, Lucila Nassif Kerbauy, Bethany Overman, Peter Thall, Mecit Kaplan, Vandana Nandivada, Indresh Kaur, Ana Nunez Cortes, Kai Cao, May Daher, Chitra Hosing, Evan N. Cohen, Partow Kebriaei, Rohtesh Mehta, Sattva Neelapu, Yago Nieto, Michael Wang, William Wierda, Michael Keating, Richard Champlin, Elizabeth J. Shpall, and Katayoun Rezvani N ENGL J MED 2020; 382:545-553
